LEVERAGE : A Multicenter, Open Label, Phase Ib/II Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

One/TwoPhase One/Two

18+Age Over 18

Blood<br/>CancersCancer LocationBlood
Cancers

Systemic therapy | Blood / Myeloma / LymphomaFollicular Lymphoma

Trial Overview Read MoreRead more

This phase 1b/2 trial is evaluating the effectiveness of two targeted therapies (venetoclax and obinutuzumab) in combination with an immunotherapy (lenaliomide) to treat follicular lymphoma.
 

This trial is treating patients with Follicular Lymphoma.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You are able to swallow medication by mouth.
  • You have been diagnosed with cancer, but have not received any treatment.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Multicenter, Open Label, Phase Ib/II Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma

Other Non-Commercial Sponsor

Peter MacCallum Cancer Centre

Summary

Patients eligible to participate in this trial will initially receive 6 cycles of obinutuzumab, venetoclax and lenaliomide. Each cycle consists of 28 days. After the initial treatment, a PET-CT scan will be conducted and depending upon the PET-CT scan results maintenance treatment may be received for up to 2 years. Followup will continue for 3 years after the last enrolled patient has received the induction treatment.

Recruiting Hospitals Read MoreRead more

PCCTU (Parkville Cancer Clinical Trials Unit) *
Parkville
Ms Marian Lieschke
marian.lieschke@petermac.org
03 8559 7140

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next